You are leaving GSKSource to visit a separate website not associated with GSKSource, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Source.GSK is not responsible for content on third-party websites.
This site is intended for US Healthcare Professionals only.
Learn about PEDIARIX with the eLecture video series
GSK has been a proud supplier of PEDIARIX for 16 years
See how the GSK suite of pediatric vaccines help maintain schedule consistency
A Guide to Administration of PEDIARIX for Nurses
Indications for PEDIARIX
PEDIARIX is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. PEDIARIX is approved for use as a three‑dose series in infants born of hepatitis B surface antigen (HBsAg)‑negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
Important Safety Information for PEDIARIX
Contraindications for PEDIARIX are: severe allergic reaction (eg, anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis-, hepatitis B-, or poliovirus-containing vaccine, or to any component of PEDIARIX; encephalopathy within 7 days of administration of a previous pertussis-containing vaccine; progressive neurologic disorders
In clinical trials, PEDIARIX was associated with higher rates of fever relative to separately administered vaccines
The decision to give PEDIARIX should be based on potential benefits and risks if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, or if adverse events (ie, temperature ≥105°F, collapse or shock-like state, persistent, inconsolable crying lasting ≥3 hours, occurring within 48 hours after vaccination; seizures within 3 days after vaccination) have occurred after receipt of a pertussis-containing vaccine
The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination with PEDIARIX
Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination with PEDIARIX should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination
In clinical trials, common adverse reactions in infants receiving PEDIARIX included injection-site reactions (pain, redness, and swelling), fever, drowsiness, irritability/fussiness, and loss of appetite
Vaccination with PEDIARIX may not result in protection in all vaccine recipients